scholarly journals Isolating the Mutator Transposable Element Insertional Mutant Gene mio16 of Maize Using Double Selected Amplification of Insertion Flanking Fragments (DSAIFF)

2012 ◽  
Vol 11 (10) ◽  
pp. 1592-1600 ◽  
Author(s):  
Wen-juan ZHONG ◽  
Mei-dong ZHANG ◽  
Liu-qi YANG ◽  
Ming-chun WANG ◽  
Yong-lian ZHENG ◽  
...  
Keyword(s):  
Transposable Element ◽  
Mutant Gene ◽  
Insertional Mutant

scholarly journals Transposable Element rbg Induces the Differential Expression of opaque-2 Mutant Gene in Two Maize o2 NILs Derived from the Same Inbred Line

PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e85159 ◽  
Author(s):  
Yan Chen ◽  
Zhiqiang Zhou ◽  
Gang Zhao ◽  
Xinhai Li ◽  
Liya Song ◽  
...  
Keyword(s):  
Transposable Element ◽  
Differential Expression ◽  
Inbred Line ◽  
Mutant Gene

Arg506GIn Factor V Mutation (Factor V Leiden) in Patients with Ischaemic Cerebrovascular Disease and Survivors of Myocardial Infarction

1995 ◽  
Vol 73 (04) ◽  
pp. 558-560 ◽  
Author(s):  
Kimmo Kontula ◽  
Antti Ylikorkala ◽  
Helena Miettinen ◽  
Alpo Vuorio ◽  
Ritva Kauppinen-Mäkelin ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Cerebrovascular Disease ◽  
Factor V Leiden ◽  
Mutant Gene ◽  
Arterial Disease ◽  
Cerebrovascular Diseases ◽  
Extensive Study ◽  
Carrier Status ◽  
Factor V ◽  
Ischaemic Attack

SummaryThe point mutation Arg506->Gln of factor V was recently shown to be an important and relatively common genetic cause of venous thromboembolism. Using a DNA technique based on polymerase chain reaction, we surveyed the blood samples of 236 patients with ischaemic stroke or a transient ischaemic attack, 122 survivors of myocardial infarction and 137 control subjects for the presence of this mutation. Although the frequency of the factor V mutation in patients with arterial disease (4.5%) was not significantly different from that in healthy blood donors (2.9%), a carrier status for this mutant gene was associated with symptoms of migraine and relatively mild angiographic abnormalities among patients with cerebrovascular disease. A more extensive study addressing the occurrence and significance of the mutant factor V mutation in patients with vasospastic cerebrovascular diseases seems to be warranted.

Oncogenomics and CYP450 Implications in Personalized Cancer Therapy

2020 ◽  
Vol 17 (2) ◽  
pp. 104-113
Author(s):  
G.K. Udayaraja ◽  
I. Arnold Emerson
Keyword(s):  
Cytochrome P450 ◽  
Cancer Treatment ◽  
Cancer Susceptibility ◽  
Mutant Gene ◽  
Genome Project ◽  
Interdisciplinary Field ◽  
Precision Therapy ◽  
Personalized Cancer Therapy ◽  
Personalized Cancer ◽  
Genetic Events

Background: The Human Genome Project has unleashed the power of genomics in clinical practice as a choice of individualized therapy, particularly in cancer treatment. Pharmacogenomics is an interdisciplinary field of genomics that deals with drug response, based on individual genetic makeup. Objective: The main genetic events associated with carcinogenesis activate oncogenes or inactivate tumor-suppressor genes. Therefore, drugs should be specific to inactivate or regulate these mutant genes and their protein products for effective cancer treatment. In this review, we summarize how polymedication decisions in cancer treatments based on the evaluation of cytochrome P450 (CYP450) polymorphisms are applied for pharmacogenetic assessment of anticancer therapy outcomes. Results: However, multiple genetic events linked, inactivating a single mutant gene product, may be insufficient to inhibit tumor progress. Thus, genomics and pharmacogenetics directly influence a patient’s response and aid in guiding clinicians to select the safest and most effective combination of medications for a cancer patient from the initial prescription. Conclusion: This review outlines the roles of oncogenes, the importance of cytochrome P450 (CYP450) in cancer susceptibility, and its impact on drug metabolism, proposing combined approaches to achieve precision therapy.

Sign in / Sign up

Export Citation Format

Share Document